Athira Pharma
ATHA | NASDAQ
$6.75
-$0.44 (-6.12%)
At close: Jan 09, 2026, 04:00 PM ET
Athira Pharma Company Profile
Company profile explainedCompany Profile
Athira Pharma, Inc., a biopharmaceutical firm in advanced clinical development and based in Bothell, Washington, focuses on creating small molecule treatments designed to revitalize neuronal function and decelerate neurological decline. Its primary therapeutic candidate, ATH-1017, is a unique small molecule that modulates HGF/MET and is capable of crossing the blood-brain barrier. This compound is currently undergoing a Phase 3 clinical trial (LIFT-AD) and a Phase 2 clinical trial (ACT-AD) for Alzheimer's disease. Additionally, ATH-1017 is in Phase 2 clinical trials for Parkinson's disease. The company also has several product candidates in earlier, preclinical stages of development, including ATH-1019 for conditions affecting the peripheral nervous system and ATH-1020 for neuropsychiatric disorders. Founded in 2011, the organization was known as M3 Biotechnology, Inc. until it rebranded to Athira Pharma, Inc. in April 2019.
Key Executives
| Name | Position |
|---|---|
| Mark J. Litton | President, Chief Executive Officer & Director |
| Robert Renninger | Chief Financial Officer |
| Javier San Martin | Chief Medical Officer |
| Julie Rathbun | Head of Investor Relations |
| Kevin Church | Chief Scientific Officer |
| Mark F. Worthington | General Counsel, Chief Compliance Officer & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 22, 2026 | 8-K | Current Report |
| Sep 03, 2026 | 3 | Filing |
| Aug 31, 2026 | SC 13D | Filing |
| Aug 26, 2026 | 8-K | Current Report |
| Aug 25, 2026 | SC 13D/A | [Amend] Filing |
| Aug 20, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 14, 2026 | 8-K | Current Report |
| Jul 10, 2026 | 4 | Filing |
| Jul 09, 2026 | 4 | Filing |
Athira Pharma
| Country | United States |
| IPO Date | Sep 18, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Mark J. Litton |
Contact Details
18706 North Creek Parkway Bothell,
Washington 98011 United States
Stock Details
| Ticker Symbol | ATHA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001620463 |
| CUSIP Number | 04746L203 |
| ISIN Number | US04746L2034 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove ATHA